# Can FDG-PET Improve the Staging of Head and Neck Cancer?

We are very close to answering this question, but need your help!

By enrolling 75 more cases to the ACRIN 6685 trial: *FDG-PET/CT Staging of Head and Neck Cancer and the Impact on N0 Neck Surgical Treatment,* we will gain valuable information for improving patient care.

PLEASE HELP SUPPORT PATIENT ENROLLMENT AT THE RESEARCH SITES BELOW.

Patient population: Patients with newly diagnosed head and neck squamous cell carcinoma being considered for surgical resection, with at least one side of the neck planned for dissection clinically N0, and at risk for occult metastasis.

ALABAMA
University of Alabama-Birmingham

ARKANSAS
University of Arkansas Medical Center

CALIFORNIA
University of Southern California

FLORIDA
University of Florida, Jacksonville

ILLINOIS
Clinical Radiologists, S.C.
Simmons Cancer Institute at Southern Illinois University School of Medicine

LOUISIANA
Biomedical Research Foundation of NW Louisiana PET Imaging Center

MARYLAND
Johns Hopkins University

MISSISSIPPI
The University of Mississippi Medical Center

MINNESOTA
Mayo Clinic

MISSOURI
Washington University
Cancer Research for the Ozarks

NEW YORK
Weill Cornell Medical College

NORTH CAROLINA
Wake Forest University School of Medicine

OKLAHOMA
University of Oklahoma Health Sciences

PENNSYLVANIA
Fox Chase Cancer Center
Thomas Jefferson University
Hospital of the University of Pennsylvania

WASHINGTON
University of Washington

INTERNATIONAL SITE
CHINA
Peking Union Medical College Hospital

Questions?

Contact ACRIN 6685 Principal Investigator Brendan C. Stack, Jr., MD
501-773-4327 • BStack@uams.edu • www.acrin.org/6685_protocol.aspx